Icon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 13.65% Baird $363 → $367 Maintains Outperform 04/26/2024 8.08% TD Cowen $343 → $349 Maintains B
Forecasting The Future: 4 Analyst Projections For Labcorp Holdings
Across the recent three months, 4 analysts have shared their insights on Labcorp Holdings (NYSE:LH), expressing a variety of opinions spanning from bullish to bearish.The following table encapsulates
Piper Sandler's Actionable Trading Ideas: 3 Positive, 3 Negative
Labcorp Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 25.91% JP Morgan $261 → $243 Maintains Overweight 04/26/2024 32.12% Truist Securities $270 → $2
Quest Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 11.68% JP Morgan $152 → $155 Maintains Neutral 04/25/2024 3.75% Barclays $138 → $144 Maintains
Here's How Much $1000 Invested In Icon 10 Years Ago Would Be Worth Today
Icon (NASDAQ:ICLR) has outperformed the market over the past 10 years by 11.78% on an annualized basis producing an average annual return of 22.28%. Currently, Icon has a market capitalization of $26.
ICON Reaffirms FY24 Revenue Guidance Of $8.48B-$8.72B Vs $8.64B Est.; Raises FY24 EPS From $14.65-$15.15 To $14.75-$15.25 Vs $14.98 Est.
Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 - $8,720 million, representing a year over year increase of 4.4% to 7.4%. Full-year 2024 adjusted earnings per share* guidance is n
ICON Updates FY24 Guidance To Incorporate Its Recent Debt Refinancing Expected To Result In A Net Interest Expense Of $200M-$210M For FY24, From The Previous Range Of $200M-$230M
Financial OutlookICON is updating its full-year 2024 guidance to incorporate its recent debt refinancing, including the impact of the successful $2 billion investment grade bond offering closed in ear
Charles River Introduces Its Vector Tech Transfer Program To Safeguard Gene Therapy Development
Fast Track and Modular frameworks facilitate product development continuity via seamless process transfer to the Company's viral vector Center of ExcellenceCharles River Laboratories International, In
Mizuho Starts Fortrea at Neutral, Cites Low Near-term Earnings Visibility
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Hedge funds made strategic adjustments to their portfolios throughout the first quarter of 2024.Firms are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on c
How Is The Market Feeling About Quest Diagnostics?
Quest Diagnostics's (NYSE:DGX) short percent of float has fallen 7.4% since its last report. The company recently reported that it has 2.80 million shares sold short, which is 2.88% of all regular sha
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Quest Diagnostics Declares $0.75 Dividend
Employers Struggle With Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
Cheating on drug tests among American workers has surged to its highest level in over 30 years, according to a lab report from Quest Diagnostics Inc (NASDAQ:DGX).The lab reported that approximately 31
Quest Diagnostics Said to Be Nearing Deal for Canada's Lifelabs
Here's How Much You Would Have Made Owning Icon Stock In The Last 20 Years
Icon (NASDAQ:ICLR) has outperformed the market over the past 20 years by 10.97% on an annualized basis producing an average annual return of 19.08%. Currently, Icon has a market capitalization of $25.
The Analyst Landscape: 7 Takes On Charles River
In the preceding three months, 7 analysts have released ratings for Charles River (NYSE:CRL), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their rec
Charles River Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 17.35% Baird $282 → $270 Maintains Outperform 03/18/2024 26.04% Argus Research $240 → $290 Main
Earnings Call Summary | Charles River(CRL.US) Q1 2024 Earnings Conference
The following is a summary of the Charles River Laboratories International, Inc. (CRL) Q1 2024 Earnings Call Transcript:Financial Performance:Charles River Laboratories reported Q1 2024 revenue of $1.